$UPXI Cashflow Statement | Understand Stock

$UPXI

$0.81 +$0.05 (6.45%) Close

$UPXI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD; shares in millions, except per-share amounts

	FY2026 12 months to Jun 30, 2026	FY2025 12 months to Jun 30, 2025	FY2024 12 months to Jun 30, 2024	FY2023 12 months to Jun 30, 2023	FY2022 12 months to Jun 30, 2022
Cash flows from operating activities
Net loss from operations
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Non-cash loss on the sale of Infusionz and select assets, net
Unrealized (gain) loss on digital assets
Digital asset revenue
Gain on the sale of VitaMedica and income from discontinued operations
Loss on the sale of New England Technology
Amortization of loan costs
Unrealized loss (gain) on digital assets
Realized loss on sale of digital assets
Digital asset revenue
Digital asset revenue conversion to USD
Realized loss on digital asset revenue conversion to USD
Amortization of loan costs
Amortization of consideration discount
Amortization of senior security original issue discount
Impairment of goodwill and intangible assets
Non-controlling interest
Loss on disposal of property and equipment
Gain on forgiveness of SBA PPP loan
Gain on extinguishment of debt
Inventory write-off
Gain on settlement of cancelled lease
Loss on impairment of building
Loss on sale of assets related to relocation of facility
Gain on sale of interactive offers
Noncontrolling interest
Change in derivative
Loss on the disposal of assets
Bad debt reserve for Amazon receivable
Reduction of acquisition payable
Lease impairment (gain on settlement)
Impairment on assets from manufacturing shut down
Impairment on acquired intangible assets
Issuance of stock for services
Shares issued for finder fee
Stock based compensation
Change in deferred tax asset
Stock-based compensation
Changes in assets and liabilities
Accounts receivable
Inventory
Prepaid expenses and other assets
Accrued liabilities related to acquisition
Operating lease payable
Accounts payable and accrued liabilities
Deferred revenue
Net cash provided by operating activities - Continuing Operations
Net cash provided by (used in) operating activities - Discontinued Operations
Net cash used in operating activities

Cash flows from investing activities
Acquisition of Infusionz, Inc., net of cash acquired
Acquisition of VitaMedica, Inc., net of cash acquired
Acquisition of Interactive Offers, Inc., net of cash acquired
Acquisition of Cygnet, Inc., net of cash acquired
Acquisition of Lucky Tail
Proceeds from the sale of VitaMedica, Inc.
Proceeds from the sale of building
Proceeds from the sale of E-core
Proceeds from the sale of Interactive Offers, net of liabilities paid

Acquisition of Cygnet Online LLC, net
Proceeds from the sale of Infusionz and selected assets
Acquisition and sale of digital assets, net
Acquisition of Cygnet Online LLC, net
Acquisition of New England Technology, Inc.
Acquisition of Cygnet
Acquisition of Interactive Offers, net of cash acquired
Proceeds from the sale of MW Products assets
Proceeds from the sale of VitaMedica, Inc.
Acquisition of digital assets
Proceeds from the sale of digital assets
Acquisition of royalty interest
Acquisition of property and equipment
Proceeds from the sale of equipment
Net cash provided by (used in) investing activities - Continuing Operations
Net cash (used in) investing activities - Discontinued Operations
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issuance of common stock
Proceeds from issuance of preferred stock
Issuance of preferred stock series A
Proceeds from exercise of warrants
Repurchases of common stock
Proceeds from short-term treasury debt
Repayment of short-term treasury debt
Proceeds from issuance of convertible notes
Stock repurchase program
Proceeds from issuance of convertible debt
Proceeds on note payable on building
Proceeds on note payable, related party
Repayment of promissory notes
Proceeds from related party advance
Repayment of related party advance
Payments of equity issuance costs
Payments of debt issuance costs
Payment on acquisition notes payable
Proceeds from issuance of notes payable
Repayment of SBA note payable
Net cash used in financing activities - Continuing Operations
Net cash (used in) provided by financing activities - Discontinued Operations
Payment on convertible note
Proceeds from the issuance of stock
Proceeds from issuance of short-term debt
Repayment of related party note payable
Repayment on note payable on building
Net cash provided by financing activities

Net decrease in cash - Continuing Operations
Net increase in cash
Net (decrease) increase in cash - Discontinued Operations
Cash, beginning of period
Cash, end of period
Supplemental Cash Flow Disclosures
Income tax paid
Issuance of common stock for acquisition of Infusionz
Issuance of common stock for conversion of notes payable and accrued interest
Repayment of Infusionz LLC debt to Upexi, Inc.
Liabilities assumed from acquisition of Infusionz
Interest paid

Income tax paid
Non-cash Investing and Financing Activities
Issuance of common stock for acquisition of Infusionz
Issuance of common stock for acquisition of VitaMedica
Issuance of debt for acquisition of VitaMedica
Liabilities assumed from acquisition of VitaMedica
Issuance of common stock for interest expenses
Issuance of commons stock for services
Issuance of common stock for acquisition of E-Core
Liabilities assumed from acquisition of E-Core
Operating assets designated as held for sale
Issuance of stock for acquisition of Interactive
Issuance of stock for acquisition of Cygnet
Liabilities assumed from acquisition of Cygnet
Stock issued for construction services
Non-cash proceeds in the sale of VitaMedica
Issuance of common stock for acquisition of Cygnet
Issuance of debt for acquisition of Cygnet
Bloomios non-cash payment of receivables, net

Bad debt expense
Issuance of stock for interest expense
Issuance of common stock for acquisition of Cygnet
Non-cash proceeds in the sale of VitaMedica
Liabilities assumed from acquisition of E-Core
Issuance of stock for acquisition of E-Core
Assets available for sale
Issuance of debt for acquisition of Cygnet
Bloomios non-cash payment of receivables, net
Issuance of common stock for the repayment of convertible notes payable
Issuance of convertible debt for digital assets acquired
Issuance of short-term debt for digital assets acquired

Comments